The role of 9-O-acetylated ganglioside D3 (CD60) and α4β1 (CD49d) expression in predicting the survival of patients with sézary syndrome

Haematologica

Volumn 95, Issue 11, 2010, Pages 1905-1912

  Scala, Enrico ^a   Abeni, Damiano ^a   Pomponi, Debora ^a   Narducci, Maria Grazia ^a   Lombardo, Giuseppe Alfonso ^a   Mari, Adriano ^a   Frontani, Marina ^a   Picchio, Maria Cristina ^a   Pilla, Maria Antonietta ^a   Caprini, Elisabetta ^a   Russo, Giandomenico ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

CD49D; CD60; Repertoire; S zary syndrome; Survival rate; TCR V

Indexed keywords

ALPHA4 INTEGRIN; CD60 ANTIGEN; CD7 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DEATH; DOWN REGULATION; ECZEMA; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; SEZARY SYNDROME; UPREGULATION;

ADULT; AGED; ANTIGENS, CD7; CD4-POSITIVE T-LYMPHOCYTES; DIPEPTIDYL PEPTIDASE 4; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GANGLIOSIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA4; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SEZARY SYNDROME; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78149237112     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026260     Document Type: Article

References (58)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition Lyon, France: IARC Press; 2008.
2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85.
3. Kelemen K, Guitart J, Kuzel TM, Goolsby CL, Peterson LC. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol. 2008;129(1):146-56.
4. Bernengo MG, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol. 2001;144(1):125-35.
5. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115(6):885-92.
6. Scala E, Russo G, Cadoni S, Narducci MG, Girardelli CR, De Pità O, et al. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7-T helper lymphocytes expansion. J Invest Dermatol. 1999;113(4):622-7.
7. Harmon CB, Witzig TE, Katzmann JA, Pittelkow MR. Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol. 1996;35(3 Pt 1):404-10.
8. Kukel S, Reinhold U, Oltermann I, Kreysel HW. Progressive increase of CD7- T cells in human blood lymphocytes with ageing. Clin Exp Immunol. 1994;98(1):163-8.
9. Scala E, Narducci MG, Amerio P, Baliva G, Simoni R, Giovannetti A, et al. T cell receptor-Vbeta analysis identifies a dominant CD60+CD26-CD49d-T cell clone in the peripheral blood of Sézary syndrome patients. J Invest Dermatol. 2002;119(1): 193-6.
10. Potoczna N, Boehncke WH, Nestle FO, Küenzlen C, Sterry W, Burg G, et al. T-cell receptor beta variable region (V beta) usage in cutaneous T-cell lymphomas (CTCL) in comparison to normal and eczematous skin. J Cutan Pathol. 1996;23(4):298-305.
11. Klemke CD, Brade J, Weckesser S, Sachse MM, Booken N, Neumaier M, et al. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers. Br J Dermatol. 2008;159(4):871-80.
12. Washington LT, Huh YO, Powers LC, Duvic M, Jones D. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002;2(1):5.
13. Bernengo MG, Quaglino P, Novelli M, Cappello N, Doveil GC, Lisa F, et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol. 1998;9(8):857-63.
14. Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol. 1995;131(9):1003-8.
15. Marti RM, Pujol RM, Servitje O, Palou J, Romagosa V, Bordes R, et al. Sezary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma. 2003;44(1):59-69.
16. Foulc P, N'Guyen JM, Dréno B. Prognostic factors in Sézary syndrome: a study of 28 patients. Br J Dermatol. 2003;149(6):1152-8.
17. Abeni D, Frontani M, Sampogna F, Sera F, Bolli S, Corona R, et al. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol. 2005;153(2):324-30.
18. Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol. 2005;153 (1):118-24.
19. Vonderheid EC, Pena J, Nowell P. Sézary cell counts in erythrodermic cutaneous Tcell lymphoma: implications for prognosis and staging. Leuk Lymphoma. 2006;47(9): 1841-56.
20. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol. 2009;48(3):243-52.
21. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009;523-31.
22. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5): 937-51.
23. Langerak AW, van Den Beemd R, Wolvers-Tettero IL, Boor PP, van Lochem EG, Hooijkaas H, et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001;98(1):165-73.
24. Beck RC, Stahl S, O'Keefe CL, Maciejewski JP, Theil KS, Hsi ED. Detection of mature Tcell leukemias by flow cytometry using anti-T-cell receptor V beta antibodies. Am J Clin Pathol. 2003;120(5):785-94.
25. Sackett DL, Haynes RB, Guyatt GH, Tugwell T. Clinical epidemiology: A Basic Science For Clinical Medicine. Boston, MA, USA: 1991.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
27. Cox RD. Regression Models and Life-Tables. J R Stat Soc B. 1972;34:187-220.
28. Rappl G, Muche JM, Abken H, Sterry W, Tilgen W, Ugurel S, et al. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome. J Am Acad Dermatol. 2001;44(3):456-61.
29. Wada T, Seki H, Konno A, Ohta K, Nunogami K, Kaneda H, et al. Developmental changes and functional properties of human memory T cell subpopulations defined by CD60 expression. Cell Immunol. 1998;187(2):117-23.
30. Kniep B, Kniep E, Ozkucur N, Barz S, Bachmann M, Malisan F, et al. 9-O-acetyl GD3 protects tumor cells from apoptosis. Int J Cancer. 2006;119(1):67-73.
31. Gocht A, Gadatsch A, Rutter G, Kniep B. CDw60: an antigen expressed in many normal tissues and in some tumours. Histochem J. 2000;32(7):447-56.
32. Heidenheim M, Hansen ER, Baadsgaard O. CDW60, which identifies the acetylated form of GD3 gangliosides, is strongly expressed in human basal cell carcinoma. Br J Dermatol. 1995;133(3):392-7.
33. Santiago MF, Liour SS, Mendez-Otero R, Yu RK. Glial-guided neuronal migration in P19 embryonal carcinoma stem cell aggregates. J Neurosci Res. 2005;81(1):9-20.
34. Mukherjee K, Chava AK, Mandal C, Dey SN, Kniep B, Chandra S, et al. O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia. J Cell Biochem. 2008;105(3):724-34.
35. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev. 2007;218:126-34.
36. Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood. 2003;102(12):4059-66.
37. Imberti L, Sottini A, Bettinardi A, Puoti M, Primi D. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science. 1991;254 (5033):860-2.
38. Vonderheid EC, Boselli CM, Conroy M, Casaus L, Espinoza LC, Venkataramani P, et al. Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol. 2005;124(3): 651-61.
39. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science. 1996; 272(5269):1755-62.
40. Cossarizza A, Barbieri D, Londei M. T cell repertoire usage in humans, from newborns to centenarians. Int Rev Immunol. 1995;12(1):41-55.
41. Gran B, Gestri D, Sottini A, Quiròs Roldàn E, Bettinardi A, Signorini S, et al. Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis. J Neuroimmunol. 1998;85(1):22-32.
42. van Den Beemd R, Boor PP, van Lochem EG, Hop WC, Langerak AW, Wolvers-Tettero IL, et al. Flow cytometric analysis of the Vbeta repertoire in healthy controls. Cytometry. 2000;40(4):336-45.
43. Van Haselen CW, Toonstra J, Preesman AH, Van Der Putte SC, Bruijnzeel-Koomen CA, van Vloten WA. Sézary syndrome in a young man with severe atopic dermatitis. Br J Dermatol. 1999;140(4):704-7.
44. Meyer N, Mazereeuw-Hautier J, Launay F, Lamant L, Paul C. Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge? Dermatology. 2009;218(2):168-71.
45. Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous T-cell lymphoma and atopy: is there an association? Br J Dermatol. 2003;149(5):1013-7.
46. Mempel M, Lina G, Hojka M, Schnopp C, Seidl HP, Schäfer T, et al. High prevalence of superantigens associated with the egc locus in Staphylococcus aureus isolates from patients with atopic eczema. Eur J Clin Microbiol Infect Dis. 2003;22(5):306-9.
47. Breuer K, HAussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol. 2002;147(1):55-61.
48. Zollner TM, Wichelhaus TA, Hartung A, Von Mallinckrodt C, Wagner TO, Brade V, et al. Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy. 2000;30(7):994-1000.
49. Nomura I, Tanaka K, Tomita H, Katsunuma T, Ohya Y, Ikeda N, et al. Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis. J Allergy Clin Immunol. 1999;104(2 Pt 1):441-6.
50. Akiyama H, Toi Y, Kanzaki H, Tada J, Arata J. Prevalence of producers of enterotoxins and toxic shock syndrome toxin-1 among Staphylococcus aureus strains isolated from atopic dermatitis lesions. Arch Dermatol Res. 1996;288(7):418-20.
51. McFadden JP, Noble WC, Camp RD. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol. 1993;128 (6):631-2.
52. Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G, et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 2000;105(4):814-9.
53. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993;54:99-166.
54. Leung DY, Gately M, Trumble A, Ferguson-Darnell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med. 1995;181(2):747-53.
55. Proft T, Fraser JD. Bacterial superantigens. Clin Exp Immunol. 2003;133(3):299-306.
56. Davison S, Allen M, Vaughan R, Barker J. Staphylococcal toxin-induced T cell proliferation in atopic eczema correlates with increased use of superantigen-reactive Vbeta-chains in cutaneous lymphocyteassociated antigen (CLA)-positive lymphocytes. Clin Exp Immunol. 2000;121(2):181-6.
57. Weber AK, Wahn U, Renz H. Superantigeninduced T cell death by apoptosis: analysis on a single cell level and effect of IFNgamma and IL-4 treatment. Int Arch Allergy Immunol. 2000;121(3):215-23.
58. Kim KS, Jacob N, Stohl W. In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin Immunol. 2003;108(3):182-9.